Objectives: The optimal intranasal sedative agent for pediatric dental procedures remains a subject of debate. We systematically reviewed and meta-analyzed head-to-head trials comparing intranasal dexmedetomidine, intranasal midazolam, oral midazolam-based regimens, and intranasal combination regimens for pediatric dental sedation. Methods: PubMed, Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials were searched (2014–2025) in accordance with the PRISMA 2020 statement. The primary outcome was procedure success rate; secondary outcomes included onset time, sedation duration, satisfactory sedation rate, satisfactory behavior rate, and adverse events. Dichotomous outcomes were pooled as risk ratios (RR) and continuous outcomes as mean differences (MD), using a DerSimonian-Laird random-effects model; the certainty of evidence was rated using GRADE. All meta-analyses were performed in RevMan Web 5.4.1, with single-arm rates presented descriptively. Results: Seventeen studies involving 1,215 children aged 1–14 years met the inclusion criteria, including 15 studies randomized controlled trials (RCTs) and 2 non-randomized studies. For the primary comparison of intranasal dexmedetomidine versus intranasal midazolam, the procedure success rate showed RR of 1.29 (95% CI: 0.86, 1.94; I 2 = 68%; p = 0.22); onset time MD of 8.79 min (95% CI: 6.70, 10.87; I 2 = 83%; p < 0.00001); sedation duration MD of 20.32 min; satisfactory sedation rate RR of 1.04 (95% CI: 0.92, 1.16; I 2 = 35%; p = 0.54); and satisfactory behavior rate RR of 1.21 (95% CI: 0.94, 1.56; p = 0.14). For intranasal versus oral sedation regimens, the procedure success rate showed an RR of 1.07 (95% CI: 0.99, 1.16; p = 0.09). For combined intranasal regimens versus single intranasal agents, the procedure success rate showed RR of 1.25 (95% CI: 0.73, 2.13; p = 0.42). Risk of bias was low to moderate in most domains, with allocation concealment and blinding being the principal sources of unclear or high risk. Conclusion: Intranasal dexmedetomidine and intranasal midazolam are both clinically effective for pediatric dental sedation. Intranasal dexmedetomidine achieved a comparable procedure success rate and satisfactory sedation rate to intranasal midazolam, while demonstrating a slower onset and longer sedation duration. No statistically significant differences were detected in the procedure success rate between intranasal and oral sedation regimens or between combined and single intranasal regimens. Further adequately powered head-to-head RCTs with standardized outcome definitions are needed. Systematic review registration: https://osf.io/qc34e/ .